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Grape seed extract (GSE) has in vitro antioxidant activity but whether or not it works in vivo is not clear. In a fully randomised,
crossover trial with 4-week treatment periods on 36 men and women with above-average vascular risk, we aimed to demonstrate
that 2g/day of GSE (1g of polyphenols) alone, or with 1g/day of added quercetin in yoghurt, favourably alters vascular function, en-
dothelial function, and degree of oxidative damage in comparison to a control yoghurt. GSE alone improved ﬂow-mediated dilatation
determined ultrasonically by an absolute 1.1% compared with control. There was no eﬀect of the combination of GSE with quercetin.
No other blood or urine measure was altered. Thus suﬃcient polyphenols from GSE appear to be absorbed to inﬂuence endothelial
nitric oxide production, and GSE has the potential to favourably inﬂuence vascular function.
BACKGROUND
Wine polyphenols have been postulated to have many
favourable eﬀects [1, 2, 3, 4] but most of this data has
been obtained in vitro [5, 6]. Grape seed extracts (GSEs)
contain a high concentration of many of the polyphe-
nols in grape skins, in particular, the proanthocyanidins,
which are also found in red wine. Green tea also con-
tains polyphenols, in particular, the catechins, which are
believed to mediate many of the cancer chemopreven-
tive eﬀects [7]. Green tea has been epidemiologically as-
sociated with protection from both cancer and heart dis-
ease [8]. Although there is abundant in vitro evidence
that polyphenols have antioxidant and anticancer eﬀects,
there is a dearth of animal and human experiments [9].
CSIRO data (unpublished) indicates that GSEs inhibit
low-density lipoprotein (LDL) oxidation and reduce aor-
tic ring constriction in vitro. Extract of oligomeric proan-
thocyanidins fromothersourcessuchasPycnogenolfrom
pine bark enhances nitric oxide (NO) production from
vascular endothelium in vitro [10]. Grape seed proantho-
cyanidin extract (GSPE, 0.1% level) has been shown to
reduce atherosclerosis in cholesterol-fed rabbits by 30%–
50% probably by inhibiting LDL oxidation as lipid lev-
els were not altered while malondialdehyde levels in the
aorta (an index of lipid oxidation) were reduced by 25%
[11]. Plasma proanthocyanidins were not detectable, sug-
gesting that absorption is very low. Rats given a dose as
a single bolus do have low (0.5µM) but detectable levels.
The dose of GSPE was equivalent to a dose of 3.5gfora
70kg human [12]. Most over-the-counter forms of GPSE
are in doses of 50–100mg with a recommendation to take
1capsule/day. This material has been available for many
years and is regarded as safe and nontoxic.
Quercetin, a ﬂavanoid prominent in onions and ap-
ples, has been epidemiologically associated with protec-
tion from coronary artery disease and cancer [13, 14]
and is now available over the counter in 300–500mg dose
forms, with daily doses of up to 1500mg. No clinical tri-
als in the cardiovascular area have been performed with
quercetin although it has been shown to inhibit mono-
cyte adhesion to endothelial cells [15]. This is believed to
be the ﬁrst step in the process of atherosclerosis. One trial
using 4g/day has shown no eﬀects on lipids, blood pres-
sure, or platelet activation in normal volunteers [16].
In this study we hypothesised that 2g/day of GSE
would improve ﬂow-mediated dilatation (FMD) and this
might be mediated by changes in the production of NO.
WealsohypothesisedthatGSEandquercetinwouldfunc-
tion as antioxidants in plasma, reduce the level of F2 iso-
prostane in urine, and possibly inﬂuence the level of ox-
idized LDL in plasma and, secondary to this, reduce the
activation of the endothelium. This would be assessed by
changes in adhesion, clotting, and ﬁbrinolytic molecules.
METHODS
Subjects
Forty-three men and women with above-average vas-
cular risk due to high cholesterol, smoking, or high
blood pressure were recruited by public advertisement2004:5 (2004) GSE and Endothelial Function 273
and screened at the Clinical Research Unit, CSIRO Health
Sciences and Nutrition, Adelaide. There were no exclu-
sion criteria on the basis of medication or consumption
of alcohol. Subjects were excluded if their body mass in-
dex (BMI) was greater than 35 or if they suﬀered from
diabetes mellitus, untreated metabolic disorders such as
thyroid or adrenal disease, liver or kidney disease, or un-
stable coronary artery disease. All subjects gave written,
informed consent and the protocol was approved by the
Human Ethics Committee of CSIRO.
The trial was 12 weeks long and consisted of 3 four-
week periods of a double-blind randomised crossover
with control and active ingredients (1g GSE from Tarac
+/− 0.5g quercetin) in 240g of yoghurt taken twice daily.
Blood samples and vascular compliance measures were
taken at baseline and at the end of each period. The
background diet was a low-polyphenol, low-quercetin
diet. This was achieved by restricting tea and coﬀee to
a maximum of 2 cups per day, restricting apples to one
per day, and forbidding red wine and onions through-
out the 12 weeks. Measures included FMD using ul-
trasound, vascular compliance using radial pulse analy-
sis (Hypertension Diagnostics Inc/PulseWave CR-2000),
fasting lipids, oxidized LDL, nitrates (to assess the antiox-
idant eﬀects), C reactive protein (CRP), von Willebrand
factor (VWF), tissue-type plasminogen activator (tPA),
plasminogen activator inhibitor 1 (PAI-1), vascular cell
adhesion molecule (VCAM1), and intercellular adhesion
molecule 1 (ICAM-1). Twenty-four-hour urine was col-
lected to measure the oxidized lipid isoprostane F2α.
FMDwasassessedinthebrachialarteryafterblockage
of blood ﬂow in the forearm with a blood pressure cuﬀ
at 200mmHg for 5 minutes. The response of the vessel 5
minutes after administration of 100µg of glyceryl trini-
trate (GTN) sublingually was also assessed [17].
Serumlipids
Serum lipids (total cholesterol, triglyceride, HDL
cholesterol) were measured on 2 consecutive days at base-
lineandattheendofeach3-weekinterventionperiod.Ve-
nous blood samples (20mL) were taken into plain tubes
after an overnight fast of 12 hour. Serum was separated
by low-speed centrifugation at 600g for 10 minutes at
5◦C (GS-6R centrifuge; Beckman, Fullerton, Calif) and
frozen at −20◦C. At the end of the study, all samples from
each subject were analysed within the same analytic run.
Total cholesterol and triacylglycerol were measured on a
Cobas-Biocentrifugalanalyzer(RocheDiagnostica,Basel,
Switzerland) using enzymatic kits (Hofmann-La Roche
Diagnostica, Basel, Switzerland) and standard control
sera. Plasma HDL-cholesterol concentrations were mea-
sured after precipitation of apoB containing lipoproteins
by PEG 6000. The coeﬃcients of variation for the individ-
ual lipids were all less than 5%. The following modiﬁca-
tion of the Friedewald equation for molar concentrations
was used to calculate LDL cholesterol in mmol/L: total
cholesterol—(triacylglycerol/2.18)—HDL cholesterol.
All other tests were enzyme linked immunosorbent
assays (ELISAs): VWF (Helena Laboratories, Melbourne
Australia), Coaliza tPA (Chromogenix, Sweden), Coaset
tPA (Chromogenix), Coaliza PAI-1 (Chromogenix),
Coatest PAI-1 (Chromogenix), oxidised LDL: Mercodia
oxidised LDL ELISA (Mercodia, Sweden), SVCAM1 (Im-
munokontact, Sweden), ICAM1 (Immunokontact), CRP
(AlphaDiagnosticInternational,Texas),8-isoprostane(8-
iso PGF2α) (Cayman Chemical), nitrate/nitrite assay kit
(Cayman Chemical).
Statisticalanalysis
Repeated measures analysis of variance was calcu-
lated with type of yoghurt as the within-subject factor
and with sex and order as the between-subject factors.
Where there was a signiﬁcant treatment eﬀect detected
by repeated measures, paired Student t tests were used
to locate diﬀerences. Bivariate correlation was conducted
using Pearson’s correlation coeﬃcient. Analyses were per-
formed with SPSS 10.0 for Windows (SPSS Inc, Chicago,
Ill). Signiﬁcance was set at P<. 05.
RESULTS AND DISCUSSION
Twelve women and twenty-four men completed the
study and one additional woman missed the last phase
of treatment. Six subjects withdrew after commencement
and 6 withdrew prior to commencement.
T h er i s kp r o ﬁ l eo fs u b j e c t sw a sa sf o l l o w s :6s u b j e c t s
had high blood pressure (5 on medication), 3 were smok-
ers, and 31 had high cholesterol (greater than 5mmol/L
o nﬁ n g e rp r i c k ) .T w ov o l u n t e e r so na t o r v a s t a t i nt ol o w e r
cholesterol stopped the medication prior to beginning
the trial. The average cholesterol was 6.5mmol/L (range
4.68 to 8.63), average age 58 years (range 34–70), weight
83.1Kg(63.1kg to 118.7kg),BMI28.4( 1 9 .8–37.5). Mean
bloodpressurewas127mm Hgsystolicand74mm Hgdi-
astolic.
Bloodpressure/vascularcompliance
There was a weak (P<. 05) trend to a lowering of sys-
tolic blood pressure over the duration of the trial with a
fall from 127mm Hg at baseline to 124mm Hg at week
12. This is quite usual in clinical trials in which blood
pressure is measured. There were no changes in any vas-
cular parameter with treatment (see Table 1).
Flow-mediateddilatationaftercompression
releaseandGTNdilatation
GSE alone produced an absolute 1.1% greater di-
latation compared with control (P<. 05) but the ad-
dition of quercetin apparently nulliﬁed this completely.
GTN-induced dilatation was not inﬂuenced by GSE but
quercetin again appeared to diminish the response com-
pared with baseline (P<. 05), but not compared with
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Table 1. Cardiovascular measures produced by the HDI compliance instrument; mean of 35 complete measures ± SD.
Baseline GSE GSE/quercetin Control
Systolic BP (mmHg) 127 ±15 124 ± 14 125 ± 11 124 ± 13
Diastolic BP (mmHg) 74 ±97 3 ± 87 3 ±10 73 ± 9
Mean BP (mmHg) 94 ±13 91 ±18 94 ±12 91 ±12
P u l s ep r e s s u r e( m m H g ) 5 3±95 1 ± 85 1 ±75 1 ± 8
Pulse rate (beats/min) 58 ±85 9 ± 85 8 ± 75 7 ± 7
Estimated cardiac ejection time (ms) 335 ±25 337 ± 24 336 ± 23 333 ± 36
Estimated stroke volume (mL) 93 ±13 92 ±12 93 ±12 94 ±12
Estimated stroke volume index (mL/m2)4 7 ±54 7 ± 44 7 ±44 7 ± 6
Estimated cardiac output (L/min) 5.4 ±0.75 .5 ±0.75 .5 ±0.75 .4 ±0.7
Estimated cardiac output index (L/min/m2)2 .8 ±0.22 .7 ±0.32 .8 ±0.32 .7 ±0.2
Large artery elasticity index 17.5 ±4.61 8 .4 ± 4.81 8 .7 ± 6.11 8 .2 ± 4.7
Small artery elasticity index 7.4 ±3.87 .4 ±3.47 .9 ±3.97 .4 ±3.2
Systemic vascular resistance 1364 ±275 1345 ± 229 1364 ± 221 1352 ± 209
Total vascular impedance 131 ±32 124 ± 33 125 ± 35 127 ± 35
Table 2. Flow-mediated dilatation as measured by ultrasound. N = 35, mean SD. Treatments with diﬀerent superscripts are diﬀerent
at P<. 05.
Baseline GSE GSE/quercetin Control
Precompression cm−2 44.3 ±6.34 5 .1 ±6.44 5 .9 ±7.24 5 .5 ± 7.3
Postcompression 46.2 ±5.84 7 .4 ±6.54 7 .6 ±7.54 7 .3 ± 7.3
(n = 30) (n = 35) (n = 32) (n = 36)
Change 1.91,2 ±1.32 .31 ±1.41 .72 ±1.01 .82 ±1.3
(4.3%) (5.1%) (3.7%) (4.0%)
Pre-GTN 44.8 ±7.14 5 .8 ±7.14 6 .9 ±7.54 6 .2 ± 7.1
Post-GTN 52.1 ±6.85 2 .7 ±6.95 2 .9 ±7.35 2 .8 ± 7.0
(n = 38) (n = 30) (n = 29) (n = 31)
Change 7.31 ±2.46 .91,2 ±2.36 .02 ±3.06 .51,2 ±1.8
(16.3%) (15.1%) (12.8%) (14.1%)
Table 3. Eﬀect of GSE and GSE/quercetin on serum lipids mean (mmol/L) ± SD.
Period 1 baseline Period 2 Period 3 Period 4 GSE GSE/quercetin Control
Total cholesterol 6.57 ±1.07 6.63 ±1.06 6.59 ±0.99 6.58 ±1.06 6.63 ± 0.93 6.64 ±1.10 6.64 ±1.05
Triglyceride 1.80 ±0.80 1.98 ±1.06 1.90 ±0.83 1.73 ±0.88 1.88 ± 0.92 1.88 ±0.85 1.92 ±1.03
HDL cholesterol 1.18 ±0.31 1.18 ±0.31 1.19 ±0.34 1.16 ±0.33 1.18 ± 0.33 1.16 ±0.34 1.15 ±0.31
LDL cholesterol 4.59 ±0.98 4.56 ±0.93 4.55 ±0.93 4.65 ±0.98 4.61 ± 0.83 4.62 ±1.00 4.63 ±0.99
This indicates that GSE favourably inﬂuences the en-
dothelium enhancing NO production, release or slowing
down oxidative destruction of it, but quercetin appears to
interferewiththis.ItisknownthatquercetininhibitsLPS-
induced NO release in RAW 264.7m a c r o p h a g e s[ 18]a n d
can act as a prooxidant in other systems [19, 20, 21]a t
both low and high levels (see Table 2).
Serumlipids
No changes were noted but none were expected. Sub-
jects were at high risk of cardiovascular disease by virtue
of the high average cholesterol (see Table 3).
Creactiveprotein
CRP is an acute-phase protein produced by the liver
in response to tissue damage or inﬂammation and may
increase 500 fold acutely [22]. It is also elevated but to
low levels by low-grade inﬂammatory conditions such as
atherosclerosis and can be used to predict clinical events
[23]. Statins whichlower cholesterol by inhibiting synthe-
sis in the liver also lower CRP and the mechanism ap-
pears to be unrelated to the degree of cholesterol lower-
ing [24]. It may be related to their antioxidant activity or
a direct anti-inﬂammatory activity. Thus in this study it
was used to check both for potential toxic eﬀects and to2004:5 (2004) GSE and Endothelial Function 275
Table 4. Eﬀect of GSE and GSE/quercetin on plasma CRP, nitrate/nitrite, and adhesion molecules. N = 35, mean SD.
Period 1 baseline Period 2 Period 3 Period 4 GSE GSE/quercetin Control
CRP (mg/L) — 3.63 ±5.01 3.48 ±4.19 3.69 ±4.17 3.40 ±3.53 3.63 ±5.10 3.73 ±4.64
Nitrate (µmol/L) 31.1 ±12.72 8 .0 ±11.03 6 .9 ±36.73 0 .0 ±13.23 5 .6 ±36.73 0 .5 ±12.42 8 .4 ±12.7
ICAM1 (µg/mL) — 0.49 ±0.10 0.49 ±0.11 0.48 ±0.11 0.49 ±0.11 0.48 ±0.11 0.49 ±0.11
VCAM1 (µg/mL) — 0.99 ±0.28 0.99 ±0.22 1.00 ±0.24 0.98 ±0.20 0.98 ±0.26 1.02 ±0.27
Table 5. Eﬀect of GSE and GSE/quercetin on clotting and ﬁbrinolytic factors. N = 35, mean SD.
Baseline Period 2 Period 3 Period 4 GSE GSE/quercetin Control
VWF (%) — 115.58 ±39.12 101.66 ±35.82 102.37 ± 35.55 109.11 ±36.06 104.50 ±39.58 106.00 ±36.40
PAI-1 ng/mL — 50.47 ±33.51 45.22 ±21.41 49.27 ±31.72 50.47 ±35.77 48.58 ±29.24 45.90 ±21.41
PAI-1 activity 16.45 ±9.72 16.27 ±9.08 16.28 ±8.05 16.28 ±10.37 15.39 ±9.30 16.78 ±10.05 16.76 ±8.13
tPA (ng/mL) — 7.235 ±3.396 6.636 ±2.350 6.857 ±2.378 6.929 ±2.686 6.908 ±2.835 6.891 ±2.766
tPA activity 1.432 ±1.204 1.295 ±0.865 1.140 ±0.715 1.269 ±1.011 1.261 ±0.822 1.146 ±0.764 1.297 ±1.011
tPA/PAI-1 activity 20.37 ±21.63 20.91 ±21.15 24.46 ±24.06 27.11 ±32.45 24.12 ±27.75 26.05 ±29.90 23.04 ±21.3
tPA/PAI-1 mass — 0.205 ±0.348 0.188 ±0.483 0.194 ±0.648 0.187 ±0.119 0.206 ±0.179 0.195 ±0.138
demonstrate a potential of GSE to act like a statin in the
vessel wall. No diﬀerences were found between periods or
treatments. One person was excluded as he had a respira-
tory infection requiring antibiotics which caused a sharp
rise in CRP levels (over a 100-fold rise) (see Table 4).
Nitrate/Nitrite
Plasma nitrate was measured as a surrogate in-
dex of NO production [25, 26]. NO is an endogenous
vasodilator produced by endothelial cells. Red wine
polyphenols enhance vasorelaxation and NO production
in vitro [27, 28]. Ethanol itself also enhances NO produc-
tion [29]. No diﬀerences were found either by period or
by treatment with or without an outlier whose value rose
6-fold in the GSE period. However, dietary nitrites and
nitrates can confound this measure quite easily so the ab-
sence of change does not mean that NO production did
not rise (see Table 4).
Adhesionmolecules
ICAM1 and VCAM1 are molecules which bind white
cells to the endothelium and reﬂect the state of the
health of the endothelium, particularly in relationship to
atherosclerosis [30, 31]. If the endothelium is damaged
by oxidized lipid, cigarette smoke, or high blood pressure,
these markers increase [32]. An antioxidant might be ex-
pected to lower the level of these markers (vitamin E does
in some studies [33]) as does a statin which lowers plasma
lipid level [34]. Polyphenols from blue and red berries re-
duce adhesion molecules in endothelial cells in vitro [35].
GSE and GSE/quercetin had no eﬀect, nor were there any
time eﬀects (see Table 4).
Clottingandﬁbrinolyticfactors
VWF mediates the binding of platelets to injured ves-
sels and protects coagulation factor VIII. It is produced
in the endothelium and is released when the endothelium
is damaged by atherosclerosis, diabetes, insulin resistance,
or hypertension [36, 37, 38]. Tissue-type plasminogen ac-
tivator is released from endothelial cells to initiate the
process of breaking down clots in the vessel by activating
plasminogen to plasmin which then breaks down ﬁbrin.
Endothelial dysfunction impairs the release of active tPA
[39] and is associated with an enhanced release of PAI-
1[ 40]. GSE and GSE/quercetin had no eﬀect on VWF,
tPA, or PAI-1 and there were no time eﬀects. In [41]d e
Maat et al found no eﬀect of black or green tea on any
of the markers we measured, but wine polyphenolics have
been shown in cultured human endothelial cells [42]t o
increase production of tPA (see Table 5).
Urineisoprostanes
8-Isoprostane (8-iso PGF2α)i sas t a b l ee n dp r o d u c t
formed from arachidonic acid by free radical action and
is measurable in plasma and urine. The level is believed to
represent the degree of oxidative stress in lipids [43, 44].
In this experiment, we saw no changes in urinary iso-
prostanes either absolute or expressed in relation to cre-
atinine to adjust for incomplete urinary collections (see
Table 6). The values measured in this study were in the
range described for subjects with type 2 diabetes. Vita-
min E has been shown to reduce plasma and urine iso-
prostanes in some studies [45, 46] but not in others [47].
Subjects with type 2 diabetes have elevated (double) level
of urinary isoprostane compared with controls and it falls
by 32% with treatment with vitamin E [48]. Ide et al [49]
found that in healthy young men vitamin E could reduce
urine isoprostane levels by 48%. Whole grains have been
found to lower isoprostane by 28% in one study [50], as
did fruit and vegetables in another study [51], although
van den Berg found no eﬀects of fruit and vegetables
[52].Teapolyphenolsdidnotalterisoprostanes[53]while
dealcoholised red wine reduced the levels in plasma with
a trend in urine [54].276 Peter M. Clifton 2004:5 (2004)
Table 6. Eﬀect of GSE and GSE/quercetin on urine isoprostane (iso PGF2α). N = 35, mean SD.
Period 2 Period 3 Period 4 GSE GSE/quercetin Control
Isoprostane (pg/mL) 617 ±348 713 ±507 709 ±578 668 ±407 741 ±644 630 ±362
Creatinine (mmol/L) 11.59 ±4.92 11.37 ±5.51 12.72 ±5.46 11.59 ±4.92 11.69 ±5.23 12.72 ±5.46
Isoprostane/creatinine pg/mg 529 ±392 561 ±327 519 ±328 534 ±362 562 ±416 513 ±254
Isoprostane excretion ng/d 1178 ±986 1243 ±1220 1107 ±743 1147 ±407 1270 ±1348 1112 ±694
Table 7. Eﬀect of GSE and GSE/quercetin on oxidised LDL levels U/L; N = 35, mean SD.
Period 2 Period 3 Period 4 GSE GSE/quercetin Control
94973±26906 94637±24862 94359±31705 95284 ±24563 99142 ±22728 98383 ±22973
Although the results are negative except for the FMD
changes, they are not incompatible with the current lit-
erature which is not uniform in its results. They are also
compatible with the observed lack of change in the lev-
els of oxidized LDL (see Table 7) in this study. There is
no published data on measurement of oxidized LDL in
plasma using this method.
There were no changes in urine chemistry, haematol-
ogy,clotting,orbiochemistrywithGSEorGSE/quercetin.
There were some time-related changes in urea and creati-
nine chloride and bicarbonate which may have been due
to warmer weather (data not shown).
CONCLUSIONS
We have demonstrated that suﬃcient antioxidant
polyphenols from GSE were absorbed to inﬂuence FMD
but no other endothelial functions were aﬀected. It is
known from rat and rabbit studies that the absorption
of proanthycyanidins from GSE is very limited. In one
rat study [55], after feeding 0.25g/kg of GSE (equiva-
lent to feeding over 20g to humans), a level of 18µg/mL
of dimer was achieved after 1 hour. In the rabbits, de-
spite an equivalent dose spread over the day, no proan-
thocyanidins were detected, even though in this model
lipidperoxidationandaorticatherosclerosiswerereduced
[11]. In vitro studies often use levels of 10–50µg/mL [6]
which is 10–20 times higher than what might be achieved
in human studies. Quercetin is known to be absorbed
and 1g/day can produce levels 23 times higher than con-
trol capsules. Despite this level and its demonstrable in
vitro antioxidant action, it has no eﬀects on platelets or
lipids [56]. Although red wine extract inhibits endothelin
(ET-1) production, neither isolated red wine polyphenols
(quercetin, resveratrol, D-,L-catechin, D-,L-epicatechin)
northeanthocyaninsdelphinidin,pelargonidin,cyanidin,
peonidin, petunidin, or malvidin aﬀect ET-1 production
[6].
Although there is no data yet relating impaired FMD
to cardiac events in subjects without coronary disease,
those patients with coronary disease who have very im-
p a i r e dF M Dh a v em o r ee v e n t s[ 57]. Subjects with im-
paired FMD are more likely to have coronary disease
on angiography [58]. Statins improve mortality and one
mechanism may be via their improvement of FMD [59].
Subjects with low acetylcholine induced forearm vasodi-
latation are more likely to have acute events [60].
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